Photo via BBC News

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

Read the original at BBC News ↗
Cite

Halpert, M. (2026, November 10). Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness. BBC News. https://www.bbc.co.uk/news/articles/crwydyde0lp3o?at_medium=RSS&at_campaign=rss

Dated from the outlet's own feed. Check the original for its byline.

BBC News · collected 2026-11-10 · by Madeline Halpert

Quick Summary

The FDA has instructed manufacturers of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound to include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. NAION occurs when blood vessels supplying the optic nerve are blocked, leading to vision loss that may be permanent. The FDA’s decision is based on its review of reports and studies indicating an increased risk of NAION in people taking these medications. Manufacturers like Novo Nordisk acknowledge patient safety concerns but maintain that a direct causal link has not been established.
Written by AI on 2026-11-10, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

The U.S. Food and Drug Administration (FDA) has ordered makers of popular weight-loss GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and permanent vision loss. The FDA announced on November 9, 2026, that the new warning follows research linking GLP-1 drugs to an increased risk of NAION, where patients may experience painless vision loss in one eye upon waking. This condition affects the optic nerve and can result in significant vision impairment or blindness. While some studies indicate a potential link between these drugs and NAION, more research is needed to fully understand the relationship, especially considering that many patients with risk factors for NAION might already have conditions like diabetes or obesity before starting GLP-1 therapy.

Written for “FDA Warns GLP-1 Drugs Eye Risk” on 2026-11-21, grounded in this article and the 11 other(s) covering the same event.

How they differ

8 outlets covered “FDA Warns GLP-1 Drugs Eye Risk”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

BBCThis outlet10 Nov

The FDA has instructed manufacturers of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound to include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. NAION occurs when blood vessels supplying the optic nerve are blocked, leading to vision loss that may be permanent. The FDA’s decision is based on its review of reports and…

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness (this article)
The Independent10 Nov

The U.S. Food and Drug Administration has required manufacturers of weight-loss drugs like Ozempic and Wegovy to include warnings about a rare eye condition called NAION that can lead to permanent vision loss. The FDA’s decision, made after reviewing reports from over 134,000 patients, found an increased risk of six cases per 100,000 people annually for those taking GLP-1 drugs compared to about four cases among…

Weight loss drugs linked to new rare side effect as new warning labels required →2 articles from The Independent on this story
NBC News9 Nov

The Food and Drug Administration has mandated that manufacturers of GLP-1 drugs, such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION) which can cause sudden blindness. This decision follows research indicating an increased risk of NAION in patients using GLP-1 medications…

FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness →
New York Post9 Nov

The FDA has mandated that manufacturers update warning labels on GLP-1 drugs like Ozempic and Wegovy to include a potential risk of nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can lead to permanent vision loss or blindness. This decision follows a study showing diabetes patients taking semaglutide are four times more likely to develop NAION compared to those not using the drug…

GLP-1 drugs must have new warning label over incurable blindness condition, says FDA →
Just the News10 Nov

The Food and Drug Administration will require weight loss drugs like Ozempic and Wegovy to include warnings about a rare side effect that can lead to permanent vision loss due to non-arteritic anterior ischemic optic neuropathy. This condition, which has been reported with all GLP-1 drugs used for obesity and diabetes management, can result in significant vision impairment. The FDA initiated this review following a…

Weight loss drugs, such as Ozempic, to carry FDA warning about rare vision-loss side effects →
Show 2 more outlets
Global News10 Nov

The FDA announced on Monday that it will require drug labels for GLP-1 medications, including Ozempic and Wegovy, to include a warning about the rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. Based on an analysis of over 125 clinical trials, the condition occurs in approximately six out of every 100,000 patients using GLP-1 drugs for at…

FDA to require vision loss warning on GLP-1 drug labels →
The Guardian10 Nov

The US FDA has issued a warning about GLP-1 weight loss medications, including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, and Sanofi’s Soliqua, due to the risk of nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. The FDA reviewed 126 clinical trials involving over 134,200 patients and found a higher incidence rate of NAION in GLP-1 users compared to…

FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications →

Where they agree and split

Framing

How the first headlines put it

Attributed to a source1
Stated as fact3
The headlines (4)

GLP-1 drugs must have new warning label over incurable blindness condition, says FDA New York Post · attributed to a source

US is requiring weight-loss drug makers to warn about possible loss of eye sight The Independent · stated as fact

FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness NBC News · stated as fact

FDA warns of rare vision-loss side effect from GLP-1 drugs CBS News · stated as fact

The full story: what happened, how it changed, and all 12 articles →

Compared with similar articles

This article reads unscored and hedges 21% of its claims. Each row says how that neighbour differs.
Global News
Hedges 2 of 18 claims Outlet record 63/100
CBS News
Hedges 4 of 25 claims Outlet record 66/100
The Guardian
Hedges 2 of 20 claims Outlet record 64/100
NBC News
Hedges 3 of 17 claims Outlet record 74/100
The Independent
Hedges 3 of 30 claims Outlet record 59/100
New York Post
Hedges 2 of 18 claims Outlet record 66/100
Just The News
Hedges 1 of 8 claims Outlet record 59/100
CBS News
Hedges 0 of 2 claims Outlet record 66/100
The Independent
Hedges 1 of 4 claims Outlet record 59/100
CBS News
Hedges 0 of 1 claims Outlet record 66/100

Story

FDA Warns GLP-1 Drugs Eye Risk
Health · 12 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
19
sentences that state something as happening or true
Uncertain
21%
4 of 19 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
65/100
BBC News's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
12
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-10 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

BBC News · 6377 article(s) · 9 correction(s) detected
Running correction rate · 9 correction(s)

Who wrote this

Madeline Halpert
30 article(s) here · 1 carrying a prediction
- Published New York City's official overseeing the closure of the city's most notorious jail hopes a new plan from Mayor Zohran Mamdani will lead to "a moment of transformation" for how people are detained in the largest US city.
"We probably couldn't make [it] happen again if we tried," Curley said.
The US was the first country to eliminate measles in the Americas thanks to vaccination campaigns, noted William Moss, a paediatric infectious disease specialist at the Johns Hopkins Bloomberg School of Public Health.
At least eight of her neighbours died in the accident - six adults and two children, New York City Mayor Zohran Mamdani said.
The child is now in hospital receiving care, Koon said, adding he was hopeful he would make a full recovery.
Some research was challenging to review because people taking GLP-1 drugs for obesity and type 2 diabetes may already have risk factors for NAION separate from the drugs, according to the regulator.
One of the runners who went to hospital told local news outlet KEYT-TV that they had lost consciousness and could not remember parts of the race.
Vice-President JD Vance, who blamed the midterm results on public anger over the war with Iran, argued the party could turn things around.
- Published President Donald Trump announced on Friday that Stephen Miller, his deputy chief of staff, would replace Susie Wiles as chief of staff.
El-Sayed has certainly shown on the campaign trail that he's willing to hit back at MAGA attacks.
Also by Madeline Halpert
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 30 articles by Madeline Halpert →

Topics

FDA Mounjaro Ozempic The US Food and Drug Administration Wegovy

Subjects

FDA ORG · 4× BBC ORG · 1× Harvard Medical School ORG · 1× Joseph Rizzo PERSON · 1× Novo ORG · 1× Novo Nordisk ORG · 1× The US Food and Drug Administration ORG · 1× the American Academy of Ophthalmology ORG · 1× the European Medicines Agency ORG · 1× the European Union ORG · 1×

Narrative

But one of the authors of the study, Harvard Medical School ophthalmology professor Dr Joseph Rizzo, said the findings were "significant but tentative", and more research was needed on the relationship between the drug and the eye condition in a more diverse population.
framing: mixed · carried by 1 article(s) · first seen 2026-11-10
Some research was challenging to review because people taking GLP-1 drugs for obesity and type 2 diabetes may already have risk factors for NAION separate from the drugs, according to the regulator.

Claims (19 extracted, 4 hedged)

- Published The US Food and Drug Administration (FDA) told makers of popular weight-loss GLP-1 drugs that they must add warning labels about a rare eye condition that can cause sudden blindness. asserted
that → publish → blindness
Manufacturers of Ozempic, Wegovy, Mounjaro and Zepbound must warn about nonarteritic anterior ischemic optic neuropathy (NAION). asserted
Manufacturers → warn → neuropathy
The disorder happens when vessels supplying blood to the optic nerves become blocked, depriving the nerves of oxygen. asserted
vessels → happen → oxygen
The condition can cause painless decreased vision in one eye, which can be permanent, the FDA said. asserted
FDA → cause → eye
In a statement to the BBC, the American Academy of Ophthalmology said "any added risk appears small, and it has not been established that these medications cause NAION". asserted
medications → say → NAION
"GLP-1 medications offer important benefits for people with diabetes, obesity, and heart disease, so our message to patients is simple," the group said. asserted
group → offer → patients
"Don't stop your medication without talking to your doctor, and if you notice sudden, painless vision loss in one eye, see an ophthalmologist promptly." asserted
you → stop → ophthalmologist
It is the most common cause of acute optic nerve injury in people over 50 years old, according to the academy. uncertain
It → accord → academy
The FDA said it conducted a detailed review of reports of NAION in GLP-1 users as well as a review of other studies and concluded there is an "increased risk of rare NAION events" in people taking the drugs. asserted
it → say → drugs
In a statement, Novo Nordisk, the manufacturer of Wegovy, one of the most popular weight-loss medications, said the company believes the data "do not establish a cause-and-effect relationship". asserted
data → say → relationship
"We recognize that NAION can have a profound impact on patients and their families. asserted
NAION → recognize → patients
Patient safety is a top priority for Novo, and we continue to monitor the safety of our medicines," the manufacturer said. asserted
manufacturer → continue → medicines
Some research was challenging to review because people taking GLP-1 drugs for obesity and type 2 diabetes may already have risk factors for NAION separate from the drugs, according to the regulator. uncertain
people → review → regulator
The FDA said it was not known why those taking GLP-1 drugs may be more at risk for the eye condition. uncertain
those → say → condition
The drugs already have warning labels for several other conditions including pancreatitis and gallbladder disease. asserted
drugs → have → pancreatitis
Some of the most common symptoms for semaglutide - a key ingredient in many GLP-1 drugs - include nausea, vomiting and stomach pain. asserted
Some → include → nausea
Last year, a safety arm of the European Medicines Agency, a part of the European Union, said up to 1 in 10,000 people taking semaglutide may be affected by NAION. uncertain
people → say → NAION
In a study published two years ago analysing 17,000 patients, US researchers found those taking semaglutide were four times more likely to be diagnosed with NAION than those not taking the drug. asserted
those → publish → drug
But one of the authors of the study, Harvard Medical School ophthalmology professor Dr Joseph Rizzo, said the findings were "significant but tentative", and more research was needed on the relationship between the drug and the eye condition in a more diverse population. asserted
research → say → population
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support